Babayeva Mariana, Assefa Haregewein, Basu Paramita, Loewy Zvi
Department of Biomedical and Pharmaceutical Sciences, Touro College of Pharmacy, New York, NY 10027, USA.
Department of Medicinal Chemistry, School of Pharmacy, College of Health Sciences, Mekelle University, 231 Tigray, Ethiopia.
Front Biosci (Elite Ed). 2022 Jan 13;14(1):1. doi: 10.31083/j.fbe1401001.
Autism spectrum disorder (ASD) is a group of disabilities with impairments in physical, verbal, and behavior areas. Regardless the growing frequency of autism, no medicine has been formed for the management of the ASD primary symptoms. The most frequently prescribed drugs are off-label. Therefore, there is necessity for an advance tactic for the treatment of autism. The endocannabinoid system has a central role in ruling emotion and social behaviors. Dysfunctions of the system donate to the behavioral deficits in autism. Therefore, the endocannabinoid system represents a potential target for the development of a novel autism therapy. Cannabis and associated compounds have produced substantial research attention as a capable therapy in neurobehavioral and neurological syndromes. In this review we examine the potential benefits of medical cannabis and related compounds in the treatment of ASD and concurrent disorders.
自闭症谱系障碍（ASD）是一组在身体、语言和行为方面存在障碍的残疾。尽管自闭症的发病率不断上升，但尚未形成用于治疗ASD主要症状的药物。最常开具的药物属于超适应症用药。因此，有必要采取一种先进的自闭症治疗策略。内源性大麻素系统在调节情绪和社会行为方面起着核心作用。该系统的功能障碍导致了自闭症患者的行为缺陷。因此，内源性大麻素系统是开发新型自闭症治疗方法的潜在靶点。大麻及相关化合物作为一种对神经行为和神经综合征有效的治疗方法，已引起了大量研究关注。在本综述中，我们研究了医用大麻及相关化合物在治疗ASD及并发疾病方面的潜在益处。
